Trial Profile
Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary) ; Thiotepa (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- Acronyms TBF
- 13 Feb 2013 New trial record